抗凝药物在慢性阻塞性肺疾病急性加重期患者中的应用效果  

Application effect of anticoagulant drugs in patients with acute exacerbation of chronic obstructive pulmonary disease

作　　者：崔琼[1] 孙建荣[2] 杨磊 CUI Qiong;SUN Jianrong;YANG Lei(Emergency Department;Geriatric Respiratory Medicine Department,Cardiovascular and Cerebrovascular Disease Hospital of Yan'an University Affiliated Hospital,Yan'an 716000,China)

机构地区：[1]延安大学附属医院心脑血管病医院急诊科,陕西延安716000 [2]延安大学附属医院心脑血管病医院老年呼吸内科,陕西延安716000

出　　处：《临床医学研究与实践》2022年第25期56-59,共4页Clinical Research and Practice

摘　　要：目的分析抗凝药物在慢性阻塞性肺疾病急性加重期(AECOPD)患者中的应用效果。方法选取2018年7月至2020年9月我院收治的130例AECOPD患者为研究对象,根据随机数字表法将其分为对照组和研究组,各65例。对照组采用常规治疗,研究组在对照组的基础上进行积极的抗凝治疗。比较两组的肺功能指标[第1秒用力呼气容积(FEV_(1))、第1秒用力呼气容积占用力肺活量比值(FEV_(1)/FVC)]、临床疗效、血清学指标[C-反应蛋白(CRP)、凝血酶原时间(PT)、纤维蛋白原(FIB)和D-二聚体(D-D)]、动脉血气指标[动脉血氧分压(PO_(2))、动脉血二氧化碳分压(PCO_(2))]、心肌损伤指标[心肌肌钙蛋白I(cTnI)]及不良反应发生情况。结果治疗前,两组的FEV_(1)、FEV_(1)/FVC比较,差异无统计学意义(P>0.05);治疗后,两组的FEV_(1)、FEV_(1)/FVC大于治疗前,差异具有统计学意义(P<0.05);治疗后,研究组的FEV_(1)、FEV_(1)/FVC大于对照组,差异具有统计学意义(P<0.05)。研究组的治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的CRP、PT、FIB、D-D水平比较,差异无统计学意义(P>0.05);治疗后1周,两组的CRP、FIB和D-D水平低于治疗前,PT长于治疗前,差异具有统计学意义(P<0.05);治疗后1周,研究组的CRP、FIB和D-D水平低于对照组,PT长于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的PO_(2)、PCO_(2)和cTnI水平比较,差异无统计学意义(P>0.05);治疗后,两组的PO_(2)高于治疗前,PCO_(2)、cTnI水平低于治疗前,差异具有统计学意义(P<0.05);治疗后,研究组的PO_(2)高于对照组,PCO_(2)、cTnI水平低于对照组,差异具有统计学意义(P<0.05)。两组均无严重不良反应发生。结论抗凝药物在AECOPD患者中的应用效果显著,有利于改善肺功能指标和动脉血气指标,值得临床推广应用。Objective To analyze the application effect of anticoagulant drugs in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods One hundred and thirty patients with AECOPD treated in our hospital from July 2018 to September 2020 were selected as the research objects,and the patients were divided into control group and study group according to the random number table method,with 65 cases in each group.The control group was given routine treatment,and the study group was given active anticoagulant therapy on the basis of the control group.The pulmonary function indexes[forced expiratory volume in one second(FEV_(1)),forced expiratory volume in one second/forced vital capacity ratio(FEV_(1)/FVC)],clinical efficacy,serological indexes[C-reactive protein(CRP),prothrombin time(PT),fibrinogen(FIB)and D-dimer(D-D)],arterial blood gas indexes[arterial partial pressure of oxygen(PO_(2)),arterialcarbon dioxide pressure(PCO_(2))],myocardial injury index[cardiac troponin I(cTnI)]and occurrence of adverse reactions were compared between the two groups.Results Before treatment,there were no significant differences in FEV_(1) and FEV_(1)/FVC between the two groups(P>0.05);after treatment,FEV_(1) and FEV_(1)/FVC in the two groups were greater than those before treatment,and the differences were statistically significant(P<0.05);after treatment,FEV_(1) and FEV_(1)/FVC in the study group were greater than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in CRP,PT,FIB and D-D levels between the two groups(P>0.05);one week after treatment,the levels of CRP,FIB and D-D in the two groups were lower than those before treatment,and PT was longer than that before treatment,and the differences were statistically significant(P<0.05);one week after treatment,CRP,FIB

关 键 词：抗凝药物 慢性阻塞性肺疾病急性加重期 肺功能指标 

分 类 号：R563.9[医药卫生—呼吸系统]